V-0046
30 evidence topics · 6 sources
Objective
Purpose stated in the phase 1 publication
Location and study date
Registered study dates, sponsor, and sites
| Field | Quoted record |
|---|---|
| Study start | “2005-04” |
| Primary completion (estimated) | “2008-10” |
| Study completion (estimated) | “2010-09” |
| Number of sites | “This study has 10 locations” |
Study design
Registered design: phase 1 dose escalation
Registered design details
| Field | Quoted record |
|---|---|
| Allocation | “Non-Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “None (Open Label)” |
Eligibility criteria
Treatment
Dose levels and schedules administered
“A total of 35 patients received single or multiple (every 28 days × 3 or weekly × 6) intravesical infusions of CG0070 at 1 of 4 dose levels (1 × 10(12), 3 × 10(12), 1 × 10(13) or 3 × 10(13) viral particles).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using maximum tolerated dose as the primary endpoint
Registered primary endpoint: maximum tolerated or maximum feasible dose
Primary goals stated at study start: safety and maximum tolerated dose
Response and pharmacokinetic assessments
“Response to treatment was based on cystoscopic assessment and biopsy or urine cytology.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Urine and plasma CG0070, and granulocyte-monocyte colony-stimulating factor were measured in all patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Registered enrollment
| Field | Quoted record |
|---|---|
| Enrollment (estimated) | “75” |
Description of analysis sets
Results
Participant disposition
Participants treated by schedule and dose range
Baseline characteristics
Tumor stage of enrolled participants
Efficacy results
Complete response rate and duration: phase 1 publication
“The complete response rate and median duration of the complete response across cohorts was 48.6% and 10.4 months, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the multidose cohorts the complete response rate for the combined groups (every 28 days and weekly × 6) was 63.6% (14 of 22 patients).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In an exploratory, retrospective assessment patients with borderline or high retinoblastoma phosphorylation who received the multidose schedules had an 81.8% complete response rate (9 of 11).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Complete response rate: congress report
Complete response at 3 months by schedule: company presentation
| Schedule | Complete response at 3 months |
|---|---|
| Single dose | “3/13 (23%)” |
| Every 28 days | “6/13 (46%)” |
| Weekly × 6 | “7/9 (78%)” |
| Multi-dose (every 28 days and weekly × 6) | “13/22 (59%)” |
| Total | “16/35 (46%)” |
Complete response at 3 months by dose: company presentation
| Dose | Complete response at 3 months |
|---|---|
| 1 × 10^12 viral particles | “8/13 (62%)” |
| 3 × 10^12 viral particles | “4/9 (44%)” |
| 1 × 10^13 viral particles | “4/10 (40%)” |
| 3 × 10^13 viral particles | “0/3 (0%)” |
Duration of complete response: company presentation
Urine GM-CSF and viral genome measurements
“High levels of granulocyte-monocyte colony-stimulating factor were detected in urine after administration in all patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Virus replication was suggested based on an increase in urine CG0070 genomes between days 2 and 5 in 58.3% of tested patients (7 of 12).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Adverse events and maximum tolerated dose: phase 1 publication
“Grade 1-2 bladder toxicities were the most common adverse events observed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A maximum tolerated dose was not reached.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Dose-limiting toxicity and flu-like illness: congress report
Adverse events at the first multi-dose level: interim congress report
Study limitations
Summary: limitations of V-0046
- Design: V-0046 was a phase 1, open-label, non-randomized dose-escalation study in 35 participants, with cohorts of three to six participants at each dose and schedule, so efficacy estimates rest on small subgroups (for example, 9 participants on the weekly × 6 schedule).
- Population: eligibility required failure of at least one prior BCG treatment and allowed G2 disease, which differs from the BCG-unresponsive definition used in BOND-003.
- Reported results differ by source: the 2012 publication reports a complete response rate of 48.6% with a median duration of 10.4 months, a 2010 congress report gives 46%, and a 2023 company presentation gives 16 of 35 participants (46%) at 3 months with a median duration of 8.4 months. The multi-dose complete response rate is 63.6% (14 of 22) in the publication and 13 of 22 (59%) in the presentation.
- The association between retinoblastoma phosphorylation and response (81.8%, 9 of 11) comes from an exploratory, retrospective assessment of a subset of 18 participants.
- The registry record lists an estimated primary completion in October 2008 and an estimated enrollment of 75 participants, against 35 participants treated.
- Only the abstract of the 2012 publication is openly available.